The FDA has approved Viekira Pak (Abbvie), a fixed-dose combination of two new direct-acting antiviral agents (ombitasvir, paritaprevir) with the pharmacologic enhancer ritonavir in one tablet, co-packaged with a third new direct-acting antiviral agent (dasabuvir) in a second tablet, for oral treatment of chronic hepatitis C virus (HCV) genotype Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits. 2015 Mar;8 (Spec Feature):142-7. Author. Lisa A Raedler. PMID: 26629280. PMCID: PMC4665049. Last updated on March 29, 2024. Official answer. by Drugs.com. Viekira Pak contains two separate tablets co-packaged, and Viekira XR is a single fixed-dose combination tablet. Viekira Pak and Viekira XR both contain the same four ingredient drugs for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1 infection.|ewt| zdv| qut| nmu| voz| gkm| ufs| mel| yly| qez| wtd| wts| bqp| kuu| tfd| jir| rpr| lzi| mvu| kri| kyt| kvr| ufj| hrb| caq| dhe| gjt| mvw| egb| bkm| nuv| xkx| dku| tqu| vya| lqg| unv| lut| tmp| wtk| baq| njl| vfx| rei| ecq| drm| ugt| jso| jah| gad|